Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/31400
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorMuriel, Javier-
dc.contributor.authorMargarit, César-
dc.contributor.authorBarrachina, Jordi-
dc.contributor.authorBallester, Purificación-
dc.contributor.authorFlor, Andrea-
dc.contributor.authorMorales, Domingo-
dc.contributor.authorHorga, José F.-
dc.contributor.authorFernández, Eduardo-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-02-09T16:31:27Z-
dc.date.available2024-02-09T16:31:27Z-
dc.date.created2018-
dc.identifier.citationBasic & Clinical Pharmacology & Toxicology . 2019 Apr;124(4):439-448es_ES
dc.identifier.issn1742-7843-
dc.identifier.urihttps://hdl.handle.net/11000/31400-
dc.description.abstractThe threats involved in the long-term opioid treatment of chronic non-cancer pain (CNCP) have increased notably. Strategies to identify at-risk patients are important because there is no clear evidence showing which screening or deprescription programmes are appropriate. Our aim was to evaluate the evidence provided by pharmacogenetics applied to predict an analgesic toxicity profile in prescription opioid use disorder (POUD) patients participating in an opioid deprescription programme. Pharmacogenetic markers were analysed in an observational, prospective deprescription programme for POUD patients (n = 88) treated for CNCP. It consisted of monitoring visits (baseline, follow-up and final), opioid rotation or discontinuation and the recording of adverse events and suspected adverse drug reactions (ADRs). Variants in OPRM1 (A118G), ABCB1 (C3435T), COMT (G472A), OPRD1 (T921C) and ARRB2 (C8622T) genes were tested by real-time PCR. Ethics committee approved the study. Wild-type OPRM1-AA genotype carriers reported a significantly higher number of adverse events than OPRM1-AG/GG (median [p25-75], 7 [5-11] vs 5 [3-9]), particularly gastrointestinal system events (90% vs 63%) such as nausea (33% vs 0%). Suspected ADRs (affecting 17% of the patients) were three times higher in males than in females (30% vs 11%). The deprescription programme was effective and safe, and it achieved a significant progressive reduction in the morphine equivalent daily dose, strong opioids and other analgesics' use, without causing any changes in pain intensity or opiate abstinence syndrome. OPRM1 gene polymorphisms could identify the risk of gastrointestinal adverse events in POUD patients. Deprescription programmes including pharmacogenetic analysis should be considered during the follow-up of this population.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent10es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectadverse eventses_ES
dc.subjectchronic paines_ES
dc.subjectopioid use disorderes_ES
dc.subjectpharmacogeneticses_ES
dc.subjectprescription opioidses_ES
dc.titlePharmacogenetics and prediction of adverse events in prescription opioid use disorder patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1111/bcpt.13155es_ES
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica


no-thumbnailVer/Abrir:

 Pharmacogenetics and prediction of adverse events in.pdf



596,5 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.